Vicuron Plummets - A Buying Opportunity?

Vicuron sinks 40% on drug setback - could this be the time to get in? Shares of Vicuron Pharmaceuticals (MICU) plunged today after the FDA told the company that its submission for its anti-fungal drug "does not currently support a labeling claim for the initial treatment of esophageal candidiasis." The stock dropped 40% to year-ago levels around 13.20. Some analysts think this could be a good buying opportunity, but we think it is still fraught with risk.

Back to news